Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18785864 | PREDICTING mRNA PROPERTIES USING LARGE LANGUAGE TRANSFORMER MODELS | July 2024 | March 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18469290 | METHODS AND SYSTEMS FOR DETECTING INSERTIONS AND DELETIONS | September 2023 | April 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18339887 | METHODS AND SYSTEMS FOR DETECTING INSERTIONS AND DELETIONS | June 2023 | January 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18115924 | IDENTIFYING CONTRAINDICATIONS ASSOCIATED WITH DYSLIPIDEMIA MANAGEMENT | March 2023 | December 2025 | Abandon | 33 | 5 | 1 | Yes | No |
| 17813535 | CROP MONITORING SYSTEM AND METHOD | July 2022 | December 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17838129 | NON-INVASIVE DETERMINATION OF LIKELY RESPONSE TO LIPID LOWERING THERAPIES FOR CARDIOVASCULAR DISEASE | June 2022 | December 2025 | Abandon | 42 | 6 | 1 | Yes | No |
| 17382472 | SYSTEMS AND METHODS FOR DETERMINING A PHYSIOLOGICAL PROFILE USING GENETIC INFORMATION | July 2021 | February 2024 | Abandon | 31 | 9 | 0 | Yes | No |
| 17417116 | HEALTH RISK ASSESSMENT METHOD | June 2021 | February 2026 | Abandon | 56 | 1 | 0 | No | No |
| 17352046 | SYSTEMS AND METHODS FOR USING MULTISCALE DATA FOR VARIABLE, PATHWAY, AND COMPOUND DETECTION | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17347261 | Kobophenol A for the treatment of Corona Virus 2 (SARS-CoV-2) infection | June 2021 | April 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17312950 | CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM BASED ON WEARABLE MONITORING METHOD | June 2021 | November 2024 | Allow | 42 | 1 | 0 | No | No |
| 17309522 | DRUG DISCOVERY AND EARLY DISEASE IDENTIFICATION PLATFORM USING ELECTRONIC HEALTH RECORDS, GENETICS AND STEM CELLS | June 2021 | September 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17325108 | REAL-TIME DETECTION OF ERRORS IN OLIGONUCLEOTIDE SYNTHESIS | May 2021 | January 2026 | Allow | 56 | 2 | 1 | Yes | No |
| 17294977 | MULTIPLEXED DROPLET-BASED SEQUENCING USING NATURAL GENETIC BARCODES | May 2021 | September 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17320976 | HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY DETECTION | May 2021 | November 2024 | Allow | 42 | 1 | 0 | No | No |
| 17293418 | METHODS OF TREATING CANCER USING TUBULIN BINDING AGENTS | May 2021 | May 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17289695 | INTELLIGENT SYSTEM AND METHODS FOR THERAPEUTIC TARGET IDENTIFICATION | April 2021 | March 2026 | Abandon | 59 | 2 | 1 | Yes | No |
| 17239118 | SYSTEM FOR EVALUATING SENSITIVITY TO ANTI-CANCER AGENT AND A COMPUTER READABLE MEDIUM STORING PROGRAMS EXECUTING AN EVALUATING METHOD | April 2021 | June 2024 | Abandon | 37 | 5 | 0 | Yes | No |
| 17287956 | Omics Detection of Nonhomologous End Joining Repair Site Signatures | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17284558 | MULTI-OMIC SEARCH ENGINE FOR INTEGRATIVE ANALYSIS OF CANCER GENOMIC AND CLINICAL DATA | April 2021 | November 2025 | Abandon | 55 | 2 | 0 | No | No |
| 17282708 | METHOD AND SYSTEM FOR BINDING AFFINITY PREDICTION AND METHOD OF GENERATING A CANDIDATE PROTEIN-BINDING PEPTIDE | April 2021 | February 2026 | Allow | 59 | 4 | 0 | Yes | No |
| 17195582 | Methods for Detecting Analytes in Excreta in an Analytical Toilet | March 2021 | March 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17192305 | SYSTEMS AND METHODS FOR DESIGNING SELF-ASSEMBLED NANOSTRUCTURES | March 2021 | July 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17191004 | POLYGENIC RISK SCORE MODIFIES RISK OF CORONARY ARTERY DISEASE CONFERRED BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL | March 2021 | May 2025 | Abandon | 51 | 1 | 0 | No | No |
| 17179395 | Data Compression for Artificial Intelligence-Based Base Calling | February 2021 | December 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 17176151 | Knowledge Distillation and Gradient Pruning-Based Compression of Artificial Intelligence-Based Base Caller | February 2021 | March 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17172380 | SYSTEM AND METHOD FOR CANCER PROGNOSIS | February 2021 | December 2025 | Abandon | 58 | 3 | 0 | No | No |
| 17166449 | SYSTEMS AND METHODS FOR MICROWAVE JAMMING OF MOLECULAR RECOGNITION | February 2021 | November 2024 | Allow | 46 | 1 | 0 | No | No |
| 17165189 | CROP MONITORING SYSTEM AND METHOD | February 2021 | October 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17146535 | SYSTEMS AND METHODS FOR MODELLING A HUMAN SUBJECT | January 2021 | June 2025 | Abandon | 53 | 2 | 0 | Yes | No |
| 17134802 | Learning Method, Mixing Ratio Prediction Method, and Prediction Device | December 2020 | February 2026 | Abandon | 60 | 4 | 0 | Yes | No |
| 17253406 | DNA METHYLATION MARKERS FOR NONINVASIVE DETECTION OF CANCER AND USES THEREOF | December 2020 | January 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 17108259 | PREDICTING ANIMAL TESTING MEASUREMENT LEVELS | December 2020 | May 2025 | Abandon | 54 | 2 | 0 | Yes | No |
| 17098477 | METHOD AND SYSTEM FOR FACILITATING OPTIMIZATION OF A CLUSTER COMPUTING NETWORK FOR SEQUENCING DATA ANALYSIS USING ADAPTIVE DATA PARALLELIZATION, AND NON-TRANSITORY STORAGE MEDIUM | November 2020 | March 2026 | Abandon | 60 | 4 | 1 | No | No |
| 16976421 | SYSTEMS AND METHODS FOR PREDICTIVE NETWORK MODELING FOR COMPUTATIONAL SYSTEMS, BIOLOGY AND DRUG TARGET DISCOVERY | August 2020 | February 2025 | Abandon | 54 | 2 | 1 | No | No |
| 16966705 | CONTROL OF RESISTENT HARMFUL ORGANISMS | July 2020 | July 2025 | Allow | 60 | 3 | 0 | Yes | No |
| 16964183 | DIGITAL PCR DETECTION APPARATUS, DIGITAL PCR QUANTITATIVE DETECTION METHOD, MULTI-VOLUME DIGITAL PCR QUANTITATIVE ANALYSIS METHOD, DIGITAL PCR DETECTION METHOD, NUCLEIC ACID DETECTION MICROSPHERE, PREPARATION METHOD OF NUCLEIC ACID DETECTION MICROSPHERE, NUCLEIC ACID DETECTION MICROSPHERE KIT AND HIGH-THROUGHPUT NUCLEIC ACID DETECTION METHOD | July 2020 | December 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16883915 | METHODS UTILIZING SINGLE CELL GENETIC DATA FOR CELL POPULATION ANALYSIS AND APPLICATIONS THEREOF | May 2020 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16850634 | SYSTEMS AND METHODS FOR TUMOR FRACTION ESTIMATION FROM SMALL VARIANTS | April 2020 | August 2025 | Allow | 60 | 5 | 0 | Yes | No |
| 16539815 | METHODS AND SYSTEMS FOR DETECTING INSERTIONS AND DELETIONS | August 2019 | February 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 16445477 | SYSTEMS AND METHODS FOR DETECTING STRUCTURAL VARIANTS | June 2019 | January 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16395066 | DETECTING FETAL SUB-CHROMOSOMAL ANEUPLOIDIES | April 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner AUGER, NOAH ANDREW works in Art Unit 1687 and has examined 36 patent applications in our dataset. With an allowance rate of 36.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 54 months.
Examiner AUGER, NOAH ANDREW's allowance rate of 36.1% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AUGER, NOAH ANDREW receive 2.67 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by AUGER, NOAH ANDREW is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.9% benefit to allowance rate for applications examined by AUGER, NOAH ANDREW. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 83.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.